cisplatin,methotrexate,carboplatin,erdafitinib,doxorubicin,avelumab,gemcitabine,sacituzumab govitecan,sacituzumab govitecan,pembrolizumab,enfortumab vedotin,nivolumab
janssen,merck,astellas,bms,pfizer,gilead sciences,seagen
['vedo', 'avelumab', 'nivolumab', 'methotrexate', 'pembro', ' vedo', 'cisplatin', 'sacituzumab', 'erdafitinib', 'urothelial', 'urothelial carcinoma', 'erda', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'carboplatin', 'doxorubicin', 'nivo', 'gemcitabine']
summary of current systemic treatment landscape for metastatic urothelial carcinoma #gu23 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday